Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Clinimix E 2.75/25 provides amino acids for protein synthesis and dextrose for caloric support in parenteral nutrition. Amino acids serve as substrates for protein synthesis, while dextrose provides a source of glucose for energy metabolism, preventing catabolism and promoting anabolism.
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% is a parenteral nutrition solution providing amino acids, dextrose, and electrolytes. The amino acids serve as substrates for protein synthesis; dextrose supplies caloric energy; electrolytes maintain acid-base balance and osmotic equilibrium.
Parenteral nutrition for patients requiring supplemental or total nutritional support,Off-label: Not typically used off-label due to specific formulation
FDA-approved: Parenteral nutrition for patients requiring intravenous nutritional support when oral or enteral nutrition is inadequate or not possible.,Off-label: Adjunctive therapy in catabolic states, burns, trauma.
Intravenous administration: Adult dose based on protein and electrolyte requirements; typical infusion rate not to exceed 4 mg/kg/min of dextrose. Daily dose should not exceed 2.5 g/kg amino acids or 25 g/kg dextrose.
Intravenous infusion: 1-2 L/day as total parenteral nutrition; typical rate 100-125 m L/hour based on caloric and nitrogen needs.
Amino acids: not applicable (endogenous turnover). Dextrose: ~1-2 hours (exogenous glucose). Electrolytes: dependent on renal function; not traditionally defined.
Not applicable as a single agent; components have varying half-lives: dextrose ~2 h (glucose), amino acids ~1-3 h (plasma clearance), electrolytes proportional to renal function
In GFR 30-59 m L/min: reduce amino acid dose by 50% and monitor electrolytes closely. If GFR <30 m L/min: avoid or use only with extreme caution, typically restrict protein to 0.6-0.8 g/kg/day and adjust electrolytes per serum levels.
Contraindicated in severe renal impairment (Cr Cl <25 m L/min) without CRRT; for Cr Cl 25-50 m L/min reduce volume by 50% and monitor electrolytes; Cr Cl >50 m L/min no adjustment.
CLINIMIX E 2.75/25 (amino acids, dextrose, electrolytes, calcium) is a parenteral nutrition solution. No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. However, amino acids and dextrose are endogenous substances; electrolyte imbalances can cause fetal harm. In first trimester: avoid unless maternal benefit outweighs risk; deficiencies in essential nutrients may be teratogenic. Second/third trimester: use only if clearly needed; monitor for hyperglycemia (risk of fetal macrosomia, neonatal hypoglycemia).
CLINIMIX E 2.75/25 is a dual-chamber bag containing amino acids and dextrose with electrolytes, including calcium. Do not use if seals are broken or if solution is discolored. Must be administered via central line due to high dextrose concentration (25%). Avoid simultaneous administration with ceftriaxone due to calcium-ceftriaxone precipitation risk. Monitor serum electrolytes, blood glucose, and liver function tests closely. Not for use in patients with severe hepatic or renal impairment.
No interactions on record
No interactions on record
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER and TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER are distinct pharmacological agents. CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER belongs to the Parenteral Nutrition Solution class and is primarily used for Parenteral nutrition for patients requiring supplemental or total nutritional supportOff-label: Not typically used off-label due to specific formulation. TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER belongs to the Parenteral Nutrition Solution class and is primarily used for FDA-approved: Parenteral nutrition for patients requiring intravenous nutritional support when oral or enteral nutrition is inadequate or not possible.Off-label: Adjunctive therapy in catabolic states, burns, trauma.. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER carries a safety status of Category C, whereas TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Amino acids are metabolized via transamination and deamination in the liver; dextrose undergoes glycolysis and enters the citric acid cycle. Electrolytes are excreted or reabsorbed renally.
Amino acids undergo deamination and transamination in the liver; dextrose is metabolized via glycolysis and the Krebs cycle; electrolytes are excreted or reabsorbed by renal mechanisms.
Amino acids: renal elimination of metabolites and urea. Dextrose: metabolized to CO2 and water, exhaled via lungs. Electrolytes: primarily renal (90-95%), minor fecal (<5%). No significant biliary excretion.
Renal: 100% (primarily as free water and electrolytes; dextrose is metabolized; amino acids are deaminated and urea is excreted renally)
Amino acids: negligible (<5% bound). Dextrose: negligible. Electrolytes: variable; calcium ~40% bound to albumin, magnesium ~30% bound to albumin, potassium and sodium minimally bound (<5%).
Negligible for most components; amino acids: <20% (primarily albumin); dextrose: none; electrolytes: variable, e.g., calcium ~50% (albumin), magnesium ~30% (albumin)
Amino acids: total body water (~0.5-0.7 L/kg). Dextrose: total body water (~0.2 L/kg initially). Electrolytes: sodium ~0.6 L/kg, potassium ~0.4 L/kg, calcium ~0.2 L/kg, magnesium ~0.3 L/kg.
Not applicable as a mixture; approximate Vd for dextrose = 0.2 L/kg (extracellular fluid); electrolytes distribute in total body water (~0.6 L/kg for sodium, ~0.5 L/kg for chloride); amino acids Vd ~0.3-0.5 L/kg
Not applicable; administered as intravenous infusion only (bioavailability 100% by IV route). No oral bioavailability.
I. V. only: 100%
Child-Pugh Class A: no adjustment necessary. Child-Pugh B: reduce amino acid dose to 0.8-1.2 g/kg/day. Child-Pugh C: avoid due to risk of encephalopathy; if essential, restrict to 0.5-0.7 g/kg/day with branched-chain amino acid enrichment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce amino acid dose by 50% and monitor ammonia; Child-Pugh C: contraindicated due to risk of encephalopathy.
Neonates and infants: 2-3 g/kg/day amino acids and 10-15 g/kg/day dextrose, titrating gradually. Children: 1-2 g/kg/day amino acids and 5-10 g/kg/day dextrose; rate not to exceed 0.2-0.4 g/kg/h dextrose. Adjust electrolytes per daily requirements.
Starting dose: 0.5-1 g amino acids/kg/day, titrated up to 2-3 g/kg/day based on weight; typical volume 100-150 m L/kg/day for infants; adjust dextrose to maintain euglycemia.
Elderly patients: start at lower end of dose range; monitor renal function and serum electrolytes closely. Typical amino acid dose 1.0-1.2 g/kg/day, dextrose dose adjusted to avoid hyperglycemia; infusion rate not to exceed 2 mg/kg/min.
Start at lower end of dosing range (e.g., 0.5-1 L/day) with slower infusion rate (e.g., 50-75 m L/hour) due to decreased renal clearance; monitor glucose and electrolytes closely.
Not for use in patients with severe electrolyte imbalances, severe liver disease, or severe renal impairment. May cause hyperglycemia, electrolyte abnormalities, or volume overload. Must be used under medical supervision.
Contains sulfites which may cause allergic-type reactions including anaphylactic symptoms and life-threatening asthmatic episodes in susceptible individuals. Sulfite sensitivity is more common in asthmatics.
No direct food interactions as this is an intravenous product. However, oral intake may be restricted or monitored due to underlying medical conditions (e.g., diabetes, renal failure). Ensure consistent carbohydrate intake if transitioning to oral feeding.
No direct food interactions, but patients may require adjustments to oral intake during parenteral nutrition transition. Avoid grapefruit juice if certain medications are co-administered (e.g., cyclosporine).
Amino acids, dextrose, and electrolytes in parenteral nutrition are not directly teratogenic. However, the solution is used for maternal nutritional support; no human data on direct fetal risks. Use only if clearly needed. No known structural teratogenicity; potential for metabolic disturbances if maternal homeostasis not maintained.
Excretion into breast milk: unknown. Components are endogenous, so transfer is likely minimal. No specific M/P ratio available. Considered probably compatible with breastfeeding, but monitor infant for electrolyte disturbances if maternal levels are abnormal.
Excretion into breast milk of components is minimal; no specific M/P ratio reported. Considered compatible with breastfeeding if maternal nutritional status is adequate. Monitor infant for metabolic or electrolyte disturbances only if maternal therapy prolonged.
Pregnancy requires increased nutritional demands; no specific dose adjustments are established. Monitor blood glucose due to insulin resistance; consider reducing dextrose infusion if hyperglycemia develops. Adjust electrolytes based on serial monitoring. Start at lower infusion rates and titrate slowly.
No specific pregnancy pharmacokinetic data. Use standard dosing adjusted for maternal weight and metabolic demands. Monitor glucose tolerance; pregnancy may require increased insulin or reduced dextrose load. Electrolyte needs may increase due to expanded plasma volume; adjust accordingly.
TRAVASOL 4.25% with dextrose 15% is a hypertonic parenteral nutrition solution; must be administered via central venous catheter. Monitor serum electrolytes, glucose, and liver function tests. Adjust rate to avoid hyperglycemia or hypoglycemia. Contains no sulfite, suitable for sulfite-sensitive patients. Check for incompatibilities with other IV additives.
This medication provides nutrition through a vein and must be given by a healthcare professional.,Report any signs of infection at the IV site (redness, swelling, pain) or allergic reactions (rash, itching, difficulty breathing).,Inform your healthcare provider if you have a history of diabetes, kidney disease, or liver problems.,This solution contains added calcium; avoid taking additional calcium supplements without doctor approval.,You may experience changes in blood sugar; symptoms of high or low blood sugar (e.g., excessive thirst, urination, shakiness) should be reported.
This medication is a form of nutrition given through a vein when you cannot eat.,Your blood sugar and electrolytes will be monitored regularly.,Report any signs of infection (redness, swelling, pain) at the catheter site.,Do not adjust the infusion rate yourself; it is controlled by healthcare staff.,Inform your healthcare provider about all other medications you are taking.